According to Caijing. Com, in 2023, about 90% of Shan Zhi Bio-Energy will be listed, and Shan Zhi Bio-Energy will raise 930 million yuan. According to this estimate, after the company goes public, the investment income of Derui Medical will be more than 10 times. The company has four international patent technology platforms: preparation of in vitro diagnostic raw materials, extraction of nucleic acid by ultrafine magnetic particles, homogeneous PCR multi-target nucleic acid detection and automatic instrument system.
Xiamen Shan Zhi Biotechnology Co., Ltd. was established on 20 10, which is a high-tech enterprise integrating research and development, production, sales and service of molecular diagnostic reagents and instruments. Shan Zhi Bio is committed to researching the world's leading nucleic acid detection technology and providing innovative overall solutions to help early detection, accurate treatment and prognosis monitoring of diseases.